What Is PT-141?

PT-141 is another name for bremelanotide, a melanocortin receptor agonist. FDA-approved Vyleesi (bremelanotide) is indicated for acquired, generalized hypoactive sexual desire disorder (HSDD) in certain premenopausal women when low desire is not due to a medical/psychiatric condition, relationship problem, or medication/substance. Off-label use or compounded versions require careful provider review.

How It Works

Bremelanotide acts centrally through melanocortin receptor pathways involved in sexual desire signaling. It is different from PDE-5 inhibitors such as sildenafil because it is not primarily a blood-flow medication. The FDA-approved product is specifically indicated for HSDD in a defined population.

What It’s Studied For

Bremelanotide was studied in HSDD clinical trials and has FDA labeling for indication, dosing, contraindications, and safety warnings. It has also been discussed off-label in other sexual-wellness contexts; FDA-approved indications are distinguished from provider-determined off-label use.

How It May Be Used in a Clinician-Supervised Program

A licensed clinician may consider PT-141 after reviewing low desire concerns, cardiovascular health, blood pressure, medications, pregnancy status, psychiatric history, relationship factors, hormone status where relevant, and whether low desire may be secondary to another condition or drug. The provider may determine it is not appropriate.

Preferred Starting Options / Dosing Notes

Many patients begin with a lower starting option so a licensed clinician can evaluate tolerance, medical history, goals, and safety factors before any adjustments are considered. The starting option shown below is informational and reflects available program data, not self-directed dosing instructions. Final medication, dose, frequency, and treatment plan are determined by a licensed clinician.

Safety Considerations

• Transient blood pressure increases and heart-rate decrease.
• Contraindication in uncontrolled hypertension or known cardiovascular disease.
• Nausea, flushing, headache, vomiting, and injection-site reactions.
• Possible focal hyperpigmentation with repeated use.
• Disclose cardiovascular disease, hypertension, kidney/liver disease, pregnancy plans, and all medications.

Some treatments may involve compounded medications when prescribed by a clinician. Compounded medications are not FDA-approved. The FDA does not evaluate compounded medications for safety, effectiveness, or quality before marketing.

Frequently Asked Questions